Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 4/20 | 0.73 |
| ▸ | JAK2 | O60674 | 4/20 | 0.65 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.62 |
| ▸ | CDK9 | P50750 | 2/20 | 0.62 |
| ▸ | CDK2 | P24941 | 3/20 | 0.58 |
| ▸ | CDK1 | P06493 | 2/20 | 0.58 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.58 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.58 |
| ▸ | PLK4 | O00444 | 4/20 | 0.57 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | CDK4 | P11802 | 1/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.56 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.55 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.55 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.55 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4517977 | 0.90 | FLT3 (0.73) | FLT3JAK2CCNT1CDK9CDK2 | |
| SCHEMBL3042306 | 0.89 | FLT3 (0.78) | FLT3JAK2CDK2CDK1CCNB1 | |
| SCHEMBL3050088 | 0.89 | CDK1 (0.73) | FLT3JAK2CCNT1CDK9CDK2 | |
| SCHEMBL3035592 | 0.88 | JAK2 (0.66) | FLT3JAK2CCNT1CDK9PLK4 | |
| SCHEMBL3049599 | 0.86 | JAK2 (0.60) | FLT3JAK2CCNT1CDK9CDK2 | |
| SCHEMBL3052529 | 0.86 | JAK2 (0.58) | FLT3JAK2CCNT1CDK9CDK2 | |
| SCHEMBL4496547 | 0.86 | FLT3 (0.59) | FLT3JAK2CCNT1CDK9CDK2 | |
| SCHEMBL4506765 | 0.85 | FLT3 (0.62) | FLT3CCNT1CDK9CDK2CDK1 | |
| SCHEMBL4508216 | 0.85 | FLT3 (0.69) | FLT3JAK2CCNT1CDK9CDK2 | |
| SCHEMBL3056269 | 0.85 | FLT3 (1.00) | FLT3JAK2CCNT1CDK9CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267707-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-10-21 | — | — | US | claimed |
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | claimed |
| EP-2040546-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2009-04-01 | — | — | EP | claimed |
| WO-2007149427-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2007-12-27 | — | — | WO | claimed |
| EP-1836194-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | Cyclacel Limited (GB) | 2007-09-26 | — | — | EP | claimed |
| WO-2006075152-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | CYCLACEL LIMITED (GB) | 2006-07-20 | — | — | WO | claimed |
| US-20100267707-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267707-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267707-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-10-21 | — | — | US | disclosed |
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| WO-2009075691-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| EP-2040546-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2007149427-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007149427-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| EP-1836194-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | Cyclacel Limited (GB) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006075152-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | CYCLACEL LIMITED (GB) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267707-A1 | Tyrosine Kinase Inhibitors | ABL1, ERBB2, MET | FLT3 11/4885JAK2 16/4885CCNT1 1100/4885 |
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | ABL1, CDK2, JAK2 | FLT3 91/4885JAK2 3/4885CCNT1 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.